Melanocortin Receptor 4 (MC4R) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Melanocortin Receptor 4 (MC4R) – Pipeline Review, H2 2016’, provides in depth analysis on Melanocortin Receptor 4 (MC4R) targeted pipeline therapeutics.

The report provides comprehensive information on the Melanocortin Receptor 4 (MC4R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)

The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects

The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AstraZeneca Plc

Mallinckrodt Plc

Obexia AG

Palatin Technologies, Inc.

Pfizer Inc.

Retrophin Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Melanocortin Receptor 4 (MC4R) Overview 7

Therapeutics Development 8

Melanocortin Receptor 4 (MC4R) - Products under Development by Stage of Development 8

Melanocortin Receptor 4 (MC4R) - Products under Development by Therapy Area 9

Melanocortin Receptor 4 (MC4R) - Products under Development by Indication 10

Melanocortin Receptor 4 (MC4R) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Unknown Stage Products 13

Melanocortin Receptor 4 (MC4R) - Products under Development by Companies 14

Melanocortin Receptor 4 (MC4R) - Products under Development by Universities/Institutes 16

Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development 25

AstraZeneca Plc 25

Mallinckrodt Plc 26

Obexia AG 27

Palatin Technologies, Inc. 28

Pfizer Inc. 29

Retrophin Inc. 30

Melanocortin Receptor 4 (MC4R) - Drug Profiles 31

(liraglutide + setmelanotide) - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

AQB-565 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

bremelanotide - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

corticotropin - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

cosyntropin - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

OBX-1201 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

PL-8905 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Proteins to Agonize MC4R for Obesity - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

setmelanotide - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecules to Agonize MC4-R for Obesity - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Small Molecules to Target Melanocortin-4 Receptor for Cachexia - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Melanocortin Receptor 4 (MC4R) - Dormant Projects 50

Melanocortin Receptor 4 (MC4R) - Discontinued Products 52

Melanocortin Receptor 4 (MC4R) - Featured News & Press Releases 53

Aug 04, 2016: Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder 53

Jul 20, 2016: Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity 53

Jul 05, 2016: Health Care Resource Use and Costs of H.P. Acthar Gel (Repository Corticotropin Injection) for Multiple Sclerosis Relapse 54

Jun 30, 2016: Catalent Announces Agreement To Commercially Supply Palatin Technologies’ New Bremelanotide Female Sexual Dysfunction Product In Pen Injectors 55

Jun 09, 2016: Mallinckrodt Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar Gel Trial in Lupus 56

Jun 06, 2016: Palatin Technologies Receives U.S. Patent Strengthening Its Melanocortin Peptide Intellectual Property 57

May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome 58

Feb 26, 2016: Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting 58

Feb 08, 2016: Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction 59

Jan 07, 2016: Rhythm Receives FDA Breakthrough Therapy Designation for Setmelanotide for Treatment of POMC Deficiency Obesity 59

Jan 07, 2016: Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome 60

Dec 10, 2015: Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction 60

Nov 09, 2015: Mallinckrodt Study Shows Acthar Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus 60

Nov 06, 2015: Rhythm Presents Cardiovascular Safety Data from Phase 1b/2a Clinical Trials of Setmelanotide in Obesity 62

Nov 06, 2015: Rhythm Presents Positive Data from Phase 1b Study of Setmelanotide for the Treatment of Genetic Obesity 62

Appendix 64

Methodology 64

Coverage 64

Secondary Research 64

Primary Research 64

Expert Panel Validation 64

Contact Us 64

Disclaimer 65

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Comparative Analysis by Unknown Stage Development, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 24

Pipeline by AstraZeneca Plc, H2 2016 25

Pipeline by Mallinckrodt Plc, H2 2016 26

Pipeline by Obexia AG, H2 2016 27

Pipeline by Palatin Technologies, Inc., H2 2016 28

Pipeline by Pfizer Inc., H2 2016 29

Pipeline by Retrophin Inc., H2 2016 30

Dormant Projects, H2 2016 50

Dormant Projects (Contd..1), H2 2016 51

Discontinued Products, H2 2016 52

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 19

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Routes of Administration, H2 2016 21

Number of Products by Stage and Routes of Administration, H2 2016 21

Number of Products by Molecule Types, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 23

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports